Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35

Benzinga · 2d ago
Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.